BACKGROUND: Many patients with cancer experience depression and anxiety, and an associated decrease in quality of life (QOL) during radiation therapy (RT). The main objective of the study was to determine the benefits of psychosocial interventions for cancer patients who received RT. METHODS:Patients with cancer (n = 178) who agreed to participate in the study were randomized to the intervention arm (n = 89) or the control arm (n = 89). Patients in the intervention group received psychosocial care during RT, whereas the control group received RT only. The benefits of the intervention were evaluated using the Zung Self-rating Depression Scale (SDS) to measure depression, the Self-rating Anxiety Scale (SAS) to assess anxiety, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) to survey health-related QOL. The association between intervention and survival was also assessed. RESULTS: Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls. In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention. There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925) CONCLUSIONS:Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT. However, the intervention was not found to reduce the risk of cancer recurrence and death. TRIAL REGISTRATION: ChiCTR-TRC-12002438.
RCT Entities:
BACKGROUND: Many patients with cancer experience depression and anxiety, and an associated decrease in quality of life (QOL) during radiation therapy (RT). The main objective of the study was to determine the benefits of psychosocial interventions for cancerpatients who received RT. METHODS:Patients with cancer (n = 178) who agreed to participate in the study were randomized to the intervention arm (n = 89) or the control arm (n = 89). Patients in the intervention group received psychosocial care during RT, whereas the control group received RT only. The benefits of the intervention were evaluated using the Zung Self-rating Depression Scale (SDS) to measure depression, the Self-rating Anxiety Scale (SAS) to assess anxiety, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) to survey health-related QOL. The association between intervention and survival was also assessed. RESULTS:Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls. In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention. There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925) CONCLUSIONS:Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT. However, the intervention was not found to reduce the risk of cancer recurrence and death. TRIAL REGISTRATION: ChiCTR-TRC-12002438.
Authors: P J Goodwin; M Leszcz; M Ennis; J Koopmans; L Vincent; H Guther; E Drysdale; M Hundleby; H M Chochinov; M Navarro; M Speca; J Hunter Journal: N Engl J Med Date: 2001-12-13 Impact factor: 91.245
Authors: M Keller; S Sommerfeldt; C Fischer; L Knight; M Riesbeck; B Löwe; C Herfarth; T Lehnert Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: L R Derogatis; G R Morrow; J Fetting; D Penman; S Piasetsky; A M Schmale; M Henrichs; C L Carnicke Journal: JAMA Date: 1983-02-11 Impact factor: 56.272
Authors: L E Carlson; M Angen; J Cullum; E Goodey; J Koopmans; L Lamont; J H MacRae; M Martin; G Pelletier; J Robinson; J S A Simpson; M Speca; L Tillotson; B D Bultz Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Shawn M McClintock; Robin B Dail; Laura S Howe-Martin; Tara K Mann; Donald E Bailey Journal: Cancer Nurs Date: 2022-01-27 Impact factor: 2.760
Authors: Ingeborg C van der Meulen; Anne M May; J Rob J de Leeuw; Ron Koole; Miriam Oosterom; Gert-Jan Hordijk; Wynand J G Ros Journal: Support Care Cancer Date: 2015-01-23 Impact factor: 3.603
Authors: Ran Li; Li Jin; Ping Hong; Zi-Hong He; Chuan-Ye Huang; Jie-Xiu Zhao; Mei Wang; Ye Tian Journal: Evid Based Complement Alternat Med Date: 2014-06-23 Impact factor: 2.629